Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Medical Information IgAN

FILSPARI (sparsentan) – Baseline Characteristics of Asian vs Non-Asian Patients in the PROTECT Study

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Hyperkalemia

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Acute Kidney Injury

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Impact on Pregnancy, Lactation, and Fertility

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – DUPLEX (Phase 3 Study): Study Design & Topline Results

Learn more
Medical Information FSGS

FILSPARI (sparsentan) Dual Receptor Antagonism in Renal Pathophysiology and Reduction of Proteinuria

Learn more
Medical Information IgAN

FILSPARI (sparsentan) – Effect on Estimated Glomerular Filtration Rate (eGFR) in IgA Nephropathy

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Decreases in Hemoglobin

Learn more
Medical Information IgAN

FILSPARI (sparsentan) – Risk Evaluation and Mitigation Strategy (REMS)

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Mechanism of Action and Pharmacology

Learn more
Medical Information IgAN

FILSPARI (sparsentan) – Effect on Proteinuria in IgA Nephropathy

Learn more
Medical Information FSGS

FILSPARI (sparsentan): Elevated Liver Transaminases and Hepatic Safety Results

Learn more
Medical Information IgAN

FILSPARI (sparsentan) – In Combination With SGLT2 Inhibitors in IgA Nephropathy

Learn more